FDA Drug Topics: The Safety Evaluation and Surveillance of Generic Drugs - November 29, 2022
FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!
On Tuesday, November 29, 2022, CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: FDA Drug Topics: The Safety Evaluation and Surveillance of Generic Drugs. In the United States, 9 out of 10 prescriptions filled are for generic drugs. The Office of Generic Drugs (OGD) within the Center for Drug Evaluation and Research (CDER) follows a rigorous review process to ensure drug products that are approved in Abbreviated New Drug Applications (ANDAs) are of high quality, safe and considered by FDA to be therapeutically equivalent to their Reference Listed Drug (RLD). This webinar provided health care professionals with information on the evaluations performed, methods, and tools used by OGD's Office of Safety and Clinical Evaluation (OSCE) to assess the safety and effectiveness of generic drugs throughout the life-cycle of the product (e.g., pre-market and post-market setting).
Register Here: https://collaboration.fda.gov/ogd112922/event/registration.html
Download Presentation Slides: The Safety Evaluation and Surveillance of Generic Drugs (PDF - 1.06MB)
Activity Outline and Continuing Education Information
If you have never attended an Adobe Connect meeting before:
Test your connection: Adobe Connect Diagnostic Test
Get a quick overview: Discover Adobe Connect Solutions
Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.
Resources For You